Αρχειοθήκη ιστολογίου

Τετάρτη 27 Ιουνίου 2018

Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib

This phase 2 randomized clinical trial investigates if topical targeting of topical tropomyosin receptor kinase (TRK) inhibitor, pegcantratinib, is safe and efficacious in treating tumors in patients with CYLD cutaneous syndrome.

https://ift.tt/2KpGysm

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου